507th Edition, May 10th, 2022

Trouble Viewing This Email: Click Here

May 10, 2022

FOUNDING MEMBER OF

Special Edition BioTalk: Dave Saunders, CTO & Co-Founder of Galen Robotics

Dave Saunders, CTO & Co-Founder of Galen Robotics, joins Rich Bendis before their 5/6/2022 Open House in Baltimore. (RSVP to OPENHOUSE@GALENROBOTICS.COM to attend) Also, view a demo of their technology at https://bit.ly/GalenRobotics. Rich and Dave and I discuss Digital Surgery, Choosing Baltimore, and their Design Philosophy.

Listen now via Google https://bit.ly/3w7lIr7, Apple https://apple.co/3MQRj6S, Spotify https://spoti.fi/3MNYfBH, Amazon https://amzn.to/3s7PTgj, and TuneIn https://bit.ly/3823iQo.

How can your BioHealth business benefit from a review by BHI industry experts? Please register for our next Entrepreneur-In-Residence (EIR) day on May 18th and find out. To sign-up for any of the EIR dates in 2022, please follow this link.

These free 1:1 virtual sessions are an opportunity to discuss your company with experts in diagnostics, therapeutics, digital health and medical devices. If you’re a growth-stage biohealth company looking for unbiased advice on your pitch deck, commercialization strategy, evidence development or entrepreneurial challenges, our EIRs can help.

To sign-up for any of the EIR dates in 2022, please follow this link.

University of Maryland Launches New Center to Bring Health Care's Vision of Tomorrow Into Focus

COLLEGE PARK, Md. (PRWEB) May 05, 2022

Ultrasound data displayed directly on a patient via augmented reality headsets. Immersive "grand rounds" for medical students and faculty even when they're in different locations. Virtual reality landscapes matched with classical opera to transport people with painful injuries outside of themselves, reducing the need for potentially addictive opioids.

These medical examples of extended reality (XR)–the umbrella term used for technology based in virtual and augmented reality or other immersive media–are already being prototyped or tested in clinical trials. But its widespread use in hospitals and other health care settings is currently hampered by technical challenges and sparse regulatory guidelines.

Virginia Based AMPEL BioSolutions' Machine Learning Breakthrough Predicts Drug Options for Inflammatory Skin Diseases

CHARLOTTESVILLE, Va., May 3, 2022 — AMPEL BioSolutions today announces a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat inflammatory skin diseases, such as Lupus, Psoriasis, Atopic Dermatitis and Scleroderma. Revealed in the peer-reviewed journal Science Advances, the paper details AMPEL’s breakthrough machine learning approach to characterize disease activity from gene expression data obtained from patient skin biopsies. The lab test, only a concept for the last few years, is now ready for development for practical use. AMPEL's initial focus was Lupus, but the test can be used for many autoimmune or inflammatory skin diseases that affect more than 35 million Americans.

AMPEL's innovative machine learning approach, which is now ready to be developed as a decision support biomarker test, could greatly impact health care by allowing physicians to identify the cause of patient disease symptoms and select appropriate treatment more precisely. AMPEL’s approach is sufficiently sensitive to detect changes in clinically uninvolved skin so that early intervention may prevent systemic flares and skin damage apparent in lesions. The application of AMPEL’s machine learning approach could also assist pharmaceutical companies in drug development and clinical trials.

Patients with chronic skin diseases often suffer from unpredictable disease activity that impacts daily activities like work and family life. Since unpredictable symptoms often result in trips to the Emergency Room, the ability to predict worsening disease and systemic involvement with routine skin biopsies has important health care and health economics implications.

Scheer Partners to Deliver More Spec-suites and Build-to-Suit Space in Maryland · BioBuzz

It’s been a big few years in the Biohealth Capital Region, especially big for commercial real estate firm Scheer Partners. After the success of buildings like 704 Quince Orchard, a 77,000-square-foot office building converted to lab space, Scheer Partners has continued to bring new buildings to market with both spec suites and build-to-suit space available for tenants of all sizes.

“Speed to market has been the tagline for the last year or so,” said Aaron Gambini, Assistant Vice President at Scheer Partners. “So it’s sort of creating move-in ready options for the market. It seems to be the way to go to start getting activity. And it’s really the next building that delivers that is the next building to lease.”

Viewport
Window
×
×
×

About BioHealth Innovation

Contact

Connect